Question

A 55-year-old on optimal HFrEF therapy remains mildly symptomatic (EF 35%). Which additional therapy has class I indication to reduce HF hospitalization and CV death?

Accepted Answer

SGLT2 inhibitor

Answer

Ivabradine for all NYHA II

Answer

Hydralazine-nitrate only in all patients

Answer

Digoxin for mortality reduction

Answer

Omega-3 fatty acids

Practice question

A 55-year-old on optimal HFrEF therapy remains mildly symptomatic (EF 35%). Which additional therapy has class I indication to reduce HF hospitalization and CV death?